VTVT
NASDAQ
US
vTv Therapeutics Inc. - Class A Common Stock
$41.17
▲ +$0.64
(+1.58%)
Vol 41K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$167.1M
ROE
-100.5%
Margin
-835.7%
D/E
0.46
Beta
0.56
52W
$13–$38
Wall Street Consensus
11 analysts · Apr 20263
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
90.9%
Buy Rating
Price Chart
Similar Stocks
ARTV
Artiva Biotherapeutics Inc
$105.3M
RNAC
Cartesian Therapeutics Inc
$187.5M
WHWK
Whitehawk Therapeutics Inc
$114.1M
NKTX
Nkarta Inc
$131.4M
ABOS
Acumen Pharmaceuticals Inc
$127.8M
KALA
KALA BIO Inc
$12.2M
IMUX
Immunic Inc
$64.2M
TNYA
Tenaya Therapeutics Inc
$154.0M
HRTX
Heron Therapeutics Inc
$238.4M
UNCY
Unicycive Therapeutics Inc
$124.0M
Earnings
Beat rate: 50.0%
Next Report
May 13, 2026
EPS Estimate: $-0.86
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.86 | — | — |
| Dec 2025 | $-1.11 | $-0.58 | +$0.53 |
| Sep 2025 | $-1.00 | $-1.08 | $-0.08 |
| Jun 2025 | $-0.84 | $-0.92 | $-0.08 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -206.4% | -144.9% | -206.4% | -206.4% | -100.5% | -100.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -835.7% | -835.7% | -835.7% | -835.7% | -835.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.46 | 0.46 |
| Current Ratio | 4.98 | 7.39 | 4.98 | 4.98 | 9.79 | 9.79 |
Key Ratios
ROA (TTM)
-47.8%
P/S (TTM)
164.33
P/B
3.4
EPS (TTM)
$-3.32
CF/Share
$-13.50
Rev Growth 3Y
-36.7%
52W High
$38.46
52W Low
$13.15
$13.15
52-Week Range
$38.46
How does VTVT compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
VTVT valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
164.3
▲
1179%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
3.4
▲
39%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
VTVT profitability vs Biotechnology peers
ROE
-100.5%
▼
49%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-835.7%
▼
191%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-47.8%
▼
2%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
VTVT financial health vs Biotechnology peers
D/E ratio
0.5
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
9.8
▲
120%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.6
▼
42%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
VTVT fundamentals radar
VTVT
Peer median
Industry
VTVT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio